Sulfonamide cannabinoid agonists and antagonists

Details Sulfonamide cannabinoid agonists and antagonists Sulfonamide cannabinoid agonists and antagonists

2007-10-09

2007-10-09

Owens, Amelia A. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C549S390000

Reexamination Certificate

active

10601757

ABSTRACT:
Cannabinoid agonists and antagonists are provided for use in the treatment of disorders such as acute and chronic pain, inflammation, loss of appetite, convulsions, multiple sclerosis, nausea and vomiting. The cannabinoid agonists and antagonists contain a sulfonamide moiety incorporated into the cannabinoid side chain, and the side chain itself may be saturated or unsaturated.

REFERENCES:
Mechoulam, R et al ‘The cannabinoids: An overview. Therapeutic implications in vomiting an dnausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection’ Pain Res Manage, vol. 6. No. 2. Summer 2001.
Walker, Cannabinoids and pain, PMID: 11854769 (2001).
Berry, Tetrahydrocannabinol and endocannabinoids in feeding and appetite, Pharmacology & Therapeutics 95 (2002) 185-190.
Smith, The safety of cannabinoids for the treatment of multiple sclerosis, Expert Opin. Drug Saf. (2005) 4(3), 443-456.
Pertwee, Inverse agonism and neutral antagonism at cannabinoid CB1 receptors, Life Sciences 76 (2005) 1307-1324.

Affiliated with

Also associated with

Rating

Sulfonamide cannabinoid agonists and antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfonamide cannabinoid agonists and antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonamide cannabinoid agonists and antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3897512